S
Shawn C Black
Researcher at Pfizer
Publications - 17
Citations - 1408
Shawn C Black is an academic researcher from Pfizer. The author has contributed to research in topics: Cannabinoid & Cannabinoid receptor. The author has an hindex of 13, co-authored 17 publications receiving 1358 citations. Previous affiliations of Shawn C Black include Johnson & Johnson Pharmaceutical Research and Development.
Papers
More filters
Journal ArticleDOI
Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKBβ
Robert S. Garofalo,Stephen J. Orena,Kristina Rafidi,Anthony J. Torchia,Jeffrey L. Stock,Audrey L. Hildebrandt,Timothy M. Coskran,Shawn C Black,Dominique Brees,Joan R. Wicks,John D. McNeish,Kevin Coleman +11 more
TL;DR: The marked hyperglycemia and loss of pancreatic beta cells and adipose tissue in Akt2/PKBbeta-deficient mice suggest that Akt 2/P KBbeta plays critical roles in glucose metabolism and the development or maintenance of proper adipOSE tissue and islet mass for which other Akt/Pkb isoforms are unable to fully compensate.
Journal ArticleDOI
Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice.
TL;DR: The hypothesis that chronic treatment of obese individuals with cannabinoid CB1 receptor antagonists is a viable pharmacologic approach to sustained weight loss is supported.
Journal Article
Cannabinoid receptor antagonists and obesity.
TL;DR: The CB1 receptor antagonist, rimonabant (SR-141716), discovered by Sanofi-Synthélabo, is in phase III clinical trials for the treatment of obesity and has been found to decrease appetite and body weight in humans.
Journal ArticleDOI
Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist.
David A. Griffith,John R. Hadcock,Shawn C Black,Philip A. Iredale,Philip A. Carpino,Paul DaSilva-Jardine,Robert F. Day,Joseph DiBrino,Robert L. Dow,Margaret S. Landis,Rebecca E. O’Connor,Dennis O. Scott +11 more
TL;DR: In vivo, compound 3a reversed cannabinoid agonist-mediated responses, reduced food intake, and increased energy expenditure and fat oxidation in rodents.
Journal ArticleDOI
In vivo myocardial infarct size reduction by a caspase inhibitor administered after the onset of ischemia.
TL;DR: This is the first report of in vivo cardioprotection by a caspase inhibitor when administered after the onset of ischemia, and it was determined that zVAD.fmk wasCardioprotective when administered before or after the start of isChemia.